Pharmaceutical Technology

JUNE 13, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

Vaccines 87

Vaccines Communication Hospitals Packaging 87

Pharma Marketing Network

JUNE 13, 2025

By Max Kopp Diabetes care is entering a new era—yet even in 2025, continuous glucose monitors (CGMs) remain out of reach for millions. Despite a decade of innovation, current CGMs often fail to meet the needs of everyday people with type 2 diabetes, particularly those in under-resourced or underserved communities. High costs, skin invasiveness, and insurance limitations act as real barriers, not just for adoption, but for long-term engagement.

Diabetes 83

Diabetes Specialty Pharmacies 83

pharmaphorum

JUNE 13, 2025

US Senators Bernie Sanders and Angus King have introduced a bill that seeks to ban direct-to-consumer (DTC) advertising by the pharma industry.

66

66

The Pharmacist

JUNE 13, 2025

Community pharmacist Athif Arif shares his experience of working with three Luton PCNs and more than 30 community pharmacies on Pharmacy First as engagement lead for Bedfordshire, Luton and Milton Keynes ICB. Victoria Vaughan (VV): How is Pharmacy First working for your community pharmacy Woodlands in Luton, Bedfordshire? Athif Arif (AA): It has enhanced the […] The post Interview: Pharmacy First saves time, prevents escalation, and frees up capacity appeared first on The Pharmacist.

Community Pharmacies 66

Community Pharmacies 66

Speaker: Jennifer Hill

Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.

World Pharma News

JUNE 13, 2025

A series of digital tests, carried out via a smartphone app, could enhance the detection of disease progression in Huntington's disease and improve the efficiency of clinical trials, finds research led by scientists at University College London (UCL) and Roche. The research, published in Brain, highlights how digitising tests designed to measure the progression of motor symptoms in people with Huntington's disease can provide a sensitive and reliable way to track changes in the function of patie

Drug Development 62

Drug Development 62

Pharma Marketing Network

JUNE 13, 2025

Artificial intelligence is rapidly transforming industries, and the pharmaceutical sector is no exception. When it comes to marketing strategies , AI is reshaping how pharma companies reach healthcare professionals (HCPs), engage patients, and optimize campaign performance. But what exactly does this mean for pharma marketers in 2025? Are we merely adding tools to the toolkit—or rewriting the entire playbook?

52

52

The Pharmacist

JUNE 13, 2025

The carton used to package two imported batches of anticoagulant Inhixa have the incorrect strength of the product written on one side, the Medicines and Healthcare products Regulatory Agency (MHRA) has warned. Pharmacists have been told to stop supplying the affected batches of 12,000 IU (120mg)/0.8 ml solution for injection’ Inhixa solution for injection immediately […] The post Anticoagulant Inhixa recalled due to typo appeared first on The Pharmacist.

Packaging 59

Packaging 59

Pharmafile

JUNE 13, 2025

The Pharmaceutical Marketing (PM) Society has partnered with the Chartered Institute of Marketing (CIM) to launch the PMS & CIM Marketing Leaders Programme – a new initiative aimed at strengthening strategic capability and standards within pharma marketing. The programme will consist of a series of three-day, in-person training sessions delivered by senior CIM course directors […] The post PM Society and CIM launch new leadership programme for pharma marketers appeared first on Pharmaf

59

59

The Guardian - Pharmaceutical Industry

JUNE 13, 2025

AviadoBio’s breakthrough therapy hopes to stop progress of FTD, which is usually diagnosed in people under 65 Behind the gleaming glass facade of an office block in east London’s Docklands, Dr Martina Esposito Soccoio is pipetting ribonucleic acid into test tubes. Here, not far from Canary Wharf’s multinational banks, a British university spinout is working on a breakthrough treatment for a form of dementia that affects millions of people worldwide.

86

86

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

European Pharmaceutical Review

JUNE 13, 2025

The Medicines and Healthcare Products regulatory agency (MHRA) has issued another Class 2 recall, bringing the total number of pharmaceutical products given this classification in the past month to three. The agency defines Class 2 as a major defect. While not life-threatening, recall action must be taken within 48 hours. Recall due to packaging error Inhixa The latest medicine to be given this classification ( drug alert number: EL(25)A/27 ) is the injectable solution Inhixa 12,000IU (120mg)/0

Packaging 52

Packaging 52

Pharmafile

JUNE 13, 2025

EpiEndo Pharmaceuticals has announced the publication of three peer-reviewed articles in Pulmonary Pharmacology and Therapeutics, highlighting the therapeutic potential of its lead asset, EP395 (glasmacinal), as an oral treatment for chronic obstructive pulmonary disease (COPD). The published data includes findings from both clinical and preclinical studies.

59

59

PharmaShots

JUNE 13, 2025

Shots: The CVMP has recommended Zenrelia (ilunocitinib) for the treatment of pruritus linked to allergic dermatitis & clinical symptoms of atopic dermatitis in dogs Opinion was based on clinical data demonstrating quality, safety, efficacy, & a favorable benefit-risk profile incl. a non-inferiority study conducted as a part of the EU approval process Elanco plans to launch Zenrelia after marketing authorization, with supply available by Q3’25 end & anticipates additional approv

59

59

pharmaphorum

JUNE 13, 2025

EVERSANA expands commercialisation portfolio with OS Therapies and Iterum Therapeutics partnerships Sara.

110

110

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

Drug Patent Watch

JUNE 13, 2025

"The Hiring Spree You Didn't See Coming: 3 Industries Where Clinical Trials Are Fueling a Surge in Legal Support As the pharmaceutical industry continues to navigate a complex landscape of patent expirations and emerging treatments, a new trend is emerging: companies are hiring lawyers at an unprecedented rate to protect their interests in the face of clinical trial data.

56

56

Pharmaceutical Commerce

JUNE 13, 2025

As the rising cost of prescription medications in the United States becomes an increasing barrier for millions of people, how can we effectively address and improve patient adherence?

52

52

Drug Channels

JUNE 13, 2025

Today’s guest post comes from Sean Wagner, VP of Client Partnerships and Carolyn Zele, Advisor, Solution Consulting at MMIT. Sean and Carolyn argue that planning for a successful drug launch must begin early—often well before Phase III. In this article, they present a six-step framework to help manufacturers align clinical development with payer expectations, patient needs, and real-world access dynamics.

52

52

Pharmafile

JUNE 13, 2025

Bristol Myers Squibb (BMS) has presented new data from its phase 3 POETYK PsA-1 trial, showing that Sotyktu (deucravacitinib) significantly improved symptoms in adults with active psoriatic arthritis (PsA) compared to placebo. Findings were shared at the 2025 European Alliance of Associations for Rheumatology (EULAR) Congress in Barcelona, Spain, taking place 11 to 14 June. […] The post Bristol Myers Squibb reports positive results for psoriatic arthritis treatment appeared first on Pharma

59

59

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

Pharmaceutical Commerce

JUNE 13, 2025

In the second part of her Pharma Commerce video interview, Kirsten Newquist, Identiv’s CEO, describes why this technology is essential for pharmaceutical safety and efficacy.

52

52

PharmaShots

JUNE 13, 2025

Shots: The P-II trial assessed barzolvolimab (Q4W: 75 or 150mg; Q8W: 300mg) vs PBO for 16wks. in 208 CSU pts unresponsive to antihistamines, followed by 36wks. of active treatment, where 75mg & PBO pts were re-randomized to 150 or 300mg; pts were then followed for 24wks. Enrolment to P-III ( EMBARQ-CSU1 & EMBARQ-CSU2 ) trials is ongoing Trial met its 1EP of significant mean UAS7 reduction at Wk. 12 across all doses, with rapid improvements by Wk. 1, sustained or deepened through Wk. 76

59

59

Pharmaceutical Business Review

JUNE 13, 2025

PiaSky will be given as the first monthly subcutaneous therapy for adults and adolescents aged 13 years or more with a minimum body weight of 40kg. Patients have a choice to self-inject PiaSky after receiving primary intravenous (IV) infusion and subsequent weekly subcutaneous (SC) starter doses during the first month of therapy. PNH is a rare and potentially fatal bone marrow disease characterised by the destruction of red blood cells.

52

52

PharmaShots

JUNE 13, 2025

Shots: The CVMP has recommended Nobivac L6 & Nobivac LoVo L6 for the active immunization of dogs against leptospirosis; EC’s decision expected by Q3’25 The vaccine protects against 6 Leptospira serovars: Canicola, Copenhageni, Bratislava, Bananal/Lianguang, Icterohaemorrhagiae, & Grippotyphosa, preventing mortality, renal carriage, renal lesions, & urinary excretion while reducing infection & clinical signs Nobivac L6 is administered as 2 doses in dogs with an interval of 4wks.,

Vaccines 59

Vaccines Immunity Immunization 59

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

The Pharmacist

JUNE 13, 2025

A former pharmacist has been appointed as the new chief standards officer at the General Pharmaceutical Council (GPhC) for a fixed term of one year. Lynsey Cleland, who was previously the GPhC’s director for Scotland, started her new post on 9 June. In her new role at the regulator, she will be responsible for overseeing […] The post New GPhC chief standards officer appointed appeared first on The Pharmacist.

52

52

PharmaShots

JUNE 13, 2025

Shots: BioNTech has entered into a definitive purchase agreement to acquire CureVac in an all-stock transaction, strengthening its mRNA tech & capabilities As per the deal, each CureVac share will be exchanged for ~$5.46 in BioNTech ADSs, implying a total equity value of ~$1.25B, with a collar-adjusted exchange ratio (0.04318 if BioNTech’s 10-day VWAP >$126.55; 0.06476 if <$84.37), resulting in CureVac shareholders owning 4–6% of BioNTech; closing expected in 2025 CureVac will become a w

59

59

pharmaphorum

JUNE 13, 2025

AstraZeneca taps China's CSPC Pharma for new drug candidates a second time – and the latest AI-focused alliance is a big one.

65

65

BioPharma Dive

JUNE 13, 2025

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an obesity medication that works differently than its popular Wegovy.

69

69

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

PharmaShots

JUNE 13, 2025

Skip to content Skip to footer NEWS TOP 20 INSIGHTS INSIGHTS+ THOUGHTSPOT INTERVIEWS VIEWPOINTS EXCLUSIVE SPOTLIGHT EVENTS MAGAZINE Subscribe Now NEWS TOP 20 INSIGHTS INSIGHTS+ THOUGHTSPOT INTERVIEWS VIEWPOINTS EXCLUSIVE SPOTLIGHT EVENTS MAGAZINE Login or Register Home Features Blog Page Blog Band Blog Standard Blog Classic Blog Classic with sidebar Blog Portfolio Blog Portfolio with sidebar Pages About 1 About 2 Subscribe Now Typography Authors 404 Page Video Playlist Video Playlist 1 Video Pla

Biosimilars 52

Biosimilars 52

Pharmacy Times

JUNE 13, 2025

In two phase 3 clinical trials, enlicitide decanoate demonstrated clinically significant reductions in low-density lipoprotein cholesterol (LDL-C) in patients with hyperlipidemia and familial hypercholesterolemia.

57

57

pharmaphorum

JUNE 13, 2025

Hopes rise for a new treatment option for people living with lupus, after UCB and Biogen reveal phase 3 data with their anti-CD40L antibody DZP

80

80